Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cartesian Therapeutics Inc shares valued at $205,797 were purchased by BARABE TIMOTHY C on Dec 04 ’25. At $6.86 per share, BARABE TIMOTHY C acquired 30,000 shares. The insider’s holdings grew to 54,366 shares worth approximately $0.37 million following the completion of this transaction.
Also, CHRISTOPHER M JEWELL purchased 26,935 shares, netting a total of over 192,585 in proceeds.
Before that, SPRINGER TIMOTHY A had added 48,595 shares to its account. In a trade valued at $508,751, the Director bought Cartesian Therapeutics Inc shares for $10.47 each. Upon closing the transaction, the insider’s holdings increased to 48,595 shares, worth approximately $4.19 million.
As published in their initiating research note from Wedbush on July 09, 2025, Cartesian Therapeutics Inc [RNAC] has been an Outperform and the price target has been revised to $38. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of August 06, 2024, TD Cowen has initiated its “Buy” rating for RNAC. Earlier on July 02, 2024, Oppenheimer downgraded its rating. Their new recommendation was “a Perform” for RNAC stock which previously was a “an Outperform”.
Analyzing RNAC Stock Performance
On last trading session, Cartesian Therapeutics Inc [NASDAQ: RNAC] rose 5.13% to $6.76. The stock’s lowest price that day was $6.41, but it reached a high of $6.82 in the same session. During the last five days, there has been a drop of approximately -9.02%. Over the course of the year, Cartesian Therapeutics Inc shares have dropped approximately -64.46%. Shares of the company reached a 52-week high of $20.12 on 01/16/25 and a 52-week low of $5.98 on 11/06/25.
Support And Resistance Levels for Cartesian Therapeutics Inc (RNAC)
According to the 24-hour chart, there is a support level at 6.50, which, if violated, would cause prices to drop to 6.25. In the upper region, resistance lies at 6.92. The next price resistance is at 7.09. RSI (Relative Strength Index) is 41.34 on the 14-day chart, showing neutral technical sentiment.
Is Cartesian Therapeutics Inc subject to short interest?
Stocks of Cartesian Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 47808.0 shares to 2.08 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 2.13 million shares. A decline of -2.3% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 17.1 of the overall float, the days-to-cover ratio (short ratio) decline to 17.1.
Which companies own the most shares of Cartesian Therapeutics Inc (RNAC)?
In terms of Cartesian Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 43 in the next 12 months, up nearly 568.74% from the previous closing price of $6.43. Analysts anticipate Cartesian Therapeutics Inc stock to reach 45 by 2025, with the lowest price target being 40. In spite of this, 0 analysts ranked Cartesian Therapeutics Inc stock as nan at the end of 2025. On June 04, 2024, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $50.
